Alliance Pharma PLC Notification of Full Year Results
04 Mars 2024 - 8:00AM
RNS Regulatory News
RNS Number : 3674F
Alliance Pharma PLC
04 March 2024
For
immediate release
|
4 March
2024
|
ALLIANCE PHARMA
PLC
("Alliance", "Company" or
"Group")
Notification of Full Year Results, Analyst
Meeting and Webcast
Alliance Pharma plc (AIM: APH), the
international healthcare group, will
announce its results for the year ended 31 December 2023 on Tuesday
9 April 2024.
A meeting for analysts will be held
at 9.30am on the day of the results at Buchanan, 107 Cheapside,
London EC2V 6DN. To register for the meeting, analysts are invited
to contact Buchanan at alliancepharma@buchanan.uk.com
A live webcast of the analyst
meeting will be accessible via the following link:
https://stream.buchanan.uk.com/broadcast/65e0c6b14fdf0119e94f5747
A recording of the webcast will be
made available following the meeting at the investor section of
Alliance's website, https://www.alliancepharmaceuticals.com/investors
For
further information:
Alliance Pharma plc
|
+ 44 (0)1249
466966
|
Cora McCallum, Head of Investor
Relations & Corporate Communications
|
+ 44
(0)1249 705168
|
ir@allianceph.com
|
|
|
|
Buchanan
|
+ 44 (0)20 7466
5000
|
Mark Court / Sophie Wills
|
|
alliancepharma@buchanan.uk.com
|
|
|
|
Deutsche Numis (Nominated Adviser and Joint
Broker)
|
+ 44 (0)20 7260
1000
|
Freddie Barnfield / Duncan Monteith
/ Sher Shah
|
|
|
|
Investec Bank plc (Joint Broker)
|
+ 44 (0)20 7597
5970
|
Patrick Robb / Maria Gomez de
Olea
|
|
About Alliance
Alliance Pharma plc (AIM: APH) is a
growing consumer healthcare company. Our purpose is to empower
people to make a positive difference to their health and wellbeing
by making our trusted and proven brands available around the
world.
We deliver organic growth through
investing in our priority brands and channels, in related
innovation, and through selective geographic expansion to increase
the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary
acquisitions.
Headquartered in the UK, the Group
employs around 285 people based in locations across Europe, North
America, and the Asia Pacific region. By outsourcing our
manufacturing and logistics we remain asset-light and focused on
maximising the value we can bring, both to our stakeholders and to
our brands.
For more information on Alliance,
please visit our website: www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NORQKNBBKBKBBNK
Alliance Pharma (LSE:APH)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Alliance Pharma (LSE:APH)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024